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over time were observed (Fig1); sigmoid growth with early
rapid lymphoid expansion and a high steady state level (A; ALC
>1000 mL-1, inﬂection point<60 days post SCT; n¼17); a lower
steady state level arrived at slowly (B; ALC 500-1000 mL-1,
inﬂectionpoint>60days;n¼14)andpoorALCrecovery (C;ALC
<500 mL-1; n¼10). Patients displaying the pattern C had the
highest rate of relapse (P¼0.015 and 0.011 compared with
patterns A and B respectively); and DLI (P¼0.009 and 0.03).
These ﬁndings indicate that immune reconstitution can be
modeled as a mathematically deﬁned logistic dynamical sys-
tem, and that lymphoid expansion in the early days following
SCT inﬂuences eventual clinical outcomeswhen ATG is used. If
this model is generalizable then it may represent a paradigm
shift away from current practice of post-transplant in-
terventions derived from population based studies.
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Viral infections are a signiﬁcant cause of morbidity and mortality
in allogeneic HSCT recipients. Previous studies by our group and
others have demonstrated that CMV, EBV, AdV, BK and HHV6 in-
fections can be treated using adoptively transferred in vitro
expanded virus-speciﬁc T-cells (VSTs). However, the list of path-
ogens linkedwithhighmorbidity/mortality continues to grow,
while VST therapy has been limited by the paucity of infor-
mation regarding immunogenic/protective T-cell target anti-
gens within many viruses. The goal of this study was to
characterize the cellular immune response to human meta-
pneumovirus (hMPV), a paramyxoviridaedetected inup to10%
of HSCT recipients and associated with mortality of up to 43%.
To identify immunodominant T-cell targetswe assessed the
cellular immune response directed against all 9 antigens
expressed by hMPV (N, M, F, SH, G,M2-1, M2-2, P, L). For T-cell
stimulation we isolated PBMCs from healthy donors, pulsed
themwith overlapping peptide libraries (15mers overlapping
by 11aa) spanning each antigen, and then expanded them in
vitro for 10 days. The resulting lines were polyclonal with a
predominanceofCD4+T-cells (mean61+/-3%,n¼24). To assess
the speciﬁcity we used an IFNg ELIspot assay and deﬁned a
hierarchy of immunodominance according to the number of
responders and the magnitude of response. F was most
frequently recognized (n¼26) and induced the highest fre-
quencyof speciﬁc cells (mean36953SFC/2x105), followed, in
descendingorder, byN(n¼23;mean23826),M(n¼23;mean
16936), M2-1 (n¼22; mean 15327), P (n¼20; mean
16734), G (n¼10; mean 6015) and L (n¼8; mean 10719).
Reactivityagainst SHandM2-2wasdetected in3 and1donors,
respectively. The VSTs were polyfunctional, producing multi-
ple cytokines (IFNg, TNFa, GM-CSF) and effector molecules
(Granzyme B) upon stimulation with cognate antigen, as
evaluated by intracellular cytokine staining, luminex and ELI-
spot. Finally,wewere able to detect T-cells speciﬁc for F,N,M2-
1 and P in the peripheral blood of a patient who cleared their
hMPV infection afterHSCT, proving the invivo relevance of our
ﬁndings. In summary we were able to generate hMPV-VSTs
and characterize the T-cell immune response directed againstthe encoded viral proteins in healthy seropositive donors. We
next plan to assess the cytolytic capacity of our hMPV-VSTs
against virus-infected targets, identify immunodominant
epitopes and ultimately generate clinical hMPV-VSTs for
adoptive transfer in patients after allogeneic HSCT.
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Introduction: Immune reconstitution is often impaired for
months to years in patients after allogeneic hematopoietic
stem cell transplantation (HSCT) which predisposes them to
a wide collection of clinical infections.
Primary herpes simplex virus (HSV) types 1 and 2 in-
fections in immune-competent hosts results in long-term
latent infections that can be associated with recurrent
reactivations. After HSCT symptomatic HSV-1 reactivation
predominantly manifests with involvement of the oropha-
ryngeal, esophageal or tracheobronchial tracts.
Without prophylaxis HSV disease after HSCT occurs in
approximately 70e80% of seropositive recipients. Although
rarely life-threatening, HSV reactivation may cause severe
oral and genital ulceration and in some cases even dissemi-
nated diseases such as encephalitis. Our center follows the
current guidelines that recommend antiviral prophylaxis for
HSV-seropositive allogeneic HSCT recipients against HSV
infection which has reduced the incidence of HSV disease in
the early phase after HSCT.
Methods: We retrospectively analyzed possible risk factors
both by univariate and multivariate analysis for HSV reac-
tivation in 382 HSV seropositive patients transplanted be-
tween 2005 and 2013 at our center. In addition we analyzed
the impact of HSV reactivation on clinical outcome in this
patient cohort with regards to; overall survival (OS), relapse
free survival (RFS) and Transplant related mortality (TRM).
Results: The cumulative incidence was 18% of early HSV
reactivation (<90 days) in the patient material. A majority
(67%) of theHSV infections occurredwithin 30days afterHSCT.
HSV infection occurred a median of 20 days (5-90) after HSCT.
The only risk factor observed for HSV reactivation both by
univariate and multivariate analysis was age of recipient
(P<0.01). The cumulative incidence of HSV reactivation in the
different age subsets were: 0-20 years: 12.5%, 21-40 years
14.9%, 41-50 years 16.9%, 51-60 years 22.9% and >60 years
24.6%. There was no signiﬁcant difference in OS, RFS or TRM in
thepatientmaterialwith regards toHSVreactivation.However,
patientswithmalignantdisease patientswithHSV reactivation
had signiﬁcantly decreased OS compared to patients with no
HSV reactivation (p¼0.02). In patients with lymphoma this
differencewasevenmoreprominent (p¼0.002).Therewasalso
a signiﬁcant decrease in RFS in this patient category (p<0.01).
Discussion: Despite antiviral prophylaxis there is still a sub-
stantial proportion of HSV reactivation in patients after HSCT.
In ourmaterialwedid not observe any risk factors except older
patient age. While the OS and RFSwas signiﬁcantly decreased
in lymphoma patients with HSV reactivation additional mea-
sures as intensiﬁed prophylaxis and additional therapy might
be considered. Future studies regarding themechanismofHSV
reactivation and lymphoid malignancies are warranted.
